Literature DB >> 21070502

Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort.

L N Clausen1, N Weis, K Astvad, K Schønning, M Fenger, H Krarup, J Bukh, T Benfield.   

Abstract

Twenty-five per cent of individuals infected with hepatitis C virus (HCV) are able to clear HCV spontaneously. Differences in host genetics are believed to affect the outcome of HCV infection. We analysed an exonic, a promoter and an intronic single nucleotide polymorphism (SNP) of the interferon-λ3 coding interleukin (IL)-28B gene to study the relationship between IL28B SNPs and outcome of HCV infection. Among 206 HIV-1-infected Europeans with evidence of HCV infection, 47 (23%) individuals had cleared HCV and 159 (77%) had developed chronic infection. The exonic rs8103142 CT, the promoter rs12979860 CT and the intronic rs11881222 AG genotypes were associated with a decreased HCV clearance rate with adjusted odds ratios (aOR) of 0.3 (95% CI, 0.1-0.7), 0.4 (95% CI, 0.2-0.8) and 0.4 (95% CI, 0.2-0.8), respectively. The haplotype block TCG CTA was associated with a decreased HCV clearance rate (aOR 0.4, 95% CI, 0.2-0.8). Further, we found significant differences in HCV RNA levels among individuals chronically infected with HCV genotype 1 for rs8103142 and rs12979860 (P ≤ 0.05). Chronically infected individuals with HCV genotype 3 and with the favourable haplotype block CTA CTA had higher median HCV RNA levels than individuals with unfavourable haplotype blocks (P ≤ 0.05). Our findings suggest that IL28B may account for some differences in HCV outcome but that other factors including the viral genotype, host genetics and the host-virus interaction are likely to influence the outcome of HCV infection.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070502     DOI: 10.1111/j.1365-2893.2010.01392.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  16 in total

1.  Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.

Authors:  Fuat Kurbanov; Mohamed Abdel-Hamid; Rachel Latanich; Jacquie Astemborski; Mostafa Mohamed; Nabiel Mh Mikhail; Mai El-Daly; Sherif El-Kafrawy; David L Thomas; Chloe L Thio
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

2.  Analysis of host genetic diversity and viral entry as sources of between-host variation in viral load.

Authors:  Andrew R Wargo; Alison M Kell; Robert J Scott; Gary H Thorgaard; Gael Kurath
Journal:  Virus Res       Date:  2012-01-30       Impact factor: 3.303

Review 3.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  IL-28B down-regulates regulatory T cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization.

Authors:  Yanping Luo; Xingming Ma; Xun Liu; Xiaoling Lu; Hongxia Niu; Hongjuan Yu; Chunxiang Bai; Jinxiu Peng; Qiaoyang Xian; Yong Wang; Bingdong Zhu
Journal:  Int Immunol       Date:  2015-10-31       Impact factor: 4.823

5.  Racial/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women.

Authors:  Monika Sarkar; Peter Bacchetti; Phyllis Tien; Elizabeth Mileti; Audrey L French; Brian R Edlin; Marla Keller; Eric Seaberg; Marek J Nowicki; Mary Young; Marion G Peters
Journal:  Dig Dis Sci       Date:  2012-11-24       Impact factor: 3.199

6.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

7.  Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.

Authors:  John E Tavis; Maureen J Donlin; Rajeev Aurora; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  Genome Med       Date:  2011-02-08       Impact factor: 11.117

8.  IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.

Authors:  Barham K Abu Dayyeh; Namrata Gupta; Kenneth E Sherman; Paul I W de Bakker; Raymond T Chung
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

Review 9.  CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution.

Authors:  Andrea De Maria; Andrea Cossarizza
Journal:  J Transl Med       Date:  2011-06-16       Impact factor: 5.531

10.  Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.

Authors:  Jannie Pedersen; Tanja B Jensen; Thomas H R Carlsen; Kristian Schønning; Peer Brehm Christensen; Alex Lund Laursen; Henrik Krarup; Jens Bukh; Nina Weis
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.